Effects of intra-arterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in lipiodol on experimental liver tumor in rats
✍ Scribed by Hiroto Egawa; Atsuhiko Maki; Keiichiro Mori; Yuzo Yamamoto; Satoshi Mitsuhashi; Kenji Bannai; Kiro Asano; Kazue Ozawa
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 555 KB
- Volume
- 44
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
Anticancer effects and biodistribution of a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in lipiodol (LPD) were investigated as an intra-arterial chemotherapy (IAC) on Walker 256 carcinosarcorna grown in the liver of 136 Wistar rats. All rats treated with KM2210 (10 mg)-LPD survived for 90 days after administration, whereas none of the rats with LPD alone were alive for more than 19 days. Histological examination revealed that there was no viable tumor cell in the encapsulated necrotic tumor at 2 1 days after administration. There was no significant liver dysfunction or leukopenia due to KM2210. The biodistribution study using [ '"C, 'HIKM22 IO-LPD solution showed that KM22 10 accumulated selectively in tumor and that the tumor-to-normalliver and tumor-to-blood ratios were 10 and 1,000, respectively, at 21 days after administration. These results suggest that KM221O has potential clinical application in the treatment of human liver cancer.